SCHEMBL257313

SCHEMBL257313

Cc1nn2c(-c3cc(F)cc(F)c3)cc(N3CCC[C@H]3CO)nc2c1I

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.41
SCN9A Q15858 1/20 0.41
ADORA2A P29274 4/20 0.40
ADORA1 P30542 4/20 0.40
BCL6 P41182 2/20 0.36
SRC P12931 2/20 0.33
SYK P43405 2/20 0.33
TACR1 P25103 1/20 0.33
TACR3 P29371 1/20 0.33
EGLN2 Q96KS0 2/20 0.33
PDK2 Q15119 2/20 0.33
PDK4 Q16654 1/20 0.33
MKNK1 Q9BUB5 1/20 0.32
MKNK2 Q9HBH9 1/20 0.32
CYP1A2 P05177 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
ADORA2B P29275 1/20 0.32
CHRM3 P20309 1/20 0.32
JAK2 O60674 1/20 0.31
NTRK1 P04629 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020616 1.00 FPR2 (0.41) FPR2SCN9AADORA2AADORA1BCL6
SCHEMBL10071863 0.91 FPR2 (0.48) FPR2SCN9AADORA2AADORA1BCL6
SCHEMBL15020745 0.91 FPR2 (0.48) FPR2SCN9AADORA2AADORA1BCL6
SCHEMBL10072121 0.88 FPR2 (0.41) FPR2SCN9AADORA2AADORA1BCL6
SCHEMBL15020911 0.88 FPR2 (0.41) FPR2SCN9AADORA2AADORA1BCL6
SCHEMBL15020900 0.85 KDM4E (0.42) FPR2SCN9AADORA2AADORA1BCL6
SCHEMBL257323 0.85 KDM4E (0.42) FPR2SCN9AADORA2AADORA1BCL6
SCHEMBL15020553 0.83 LMNA (0.44) FPR2SCN9AADORA2AADORA1BCL6
SCHEMBL256947 0.83 LMNA (0.44) FPR2SCN9AADORA2AADORA1BCL6
SCHEMBL15020602 0.82 FPR2 (0.38) FPR2SCN9AADORA2AADORA1BCL6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 FPR2 2908/4885SCN9A 615/4885ADORA2A 1193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.